Role of embolic protection devices in ostial saphenous vein graft lesions
Background Although embolic protection devices (EPDs) have been shown to be beneficial in saphenous vein graft (SVG) lesions, their role in the subgroup of ostial SVG lesions has received limited study. Methods The coronary angiograms and procedural outcomes of 109 patients undergoing stenting of 11...
Saved in:
Published in | Catheterization and cardiovascular interventions Vol. 80; no. 7; pp. 1120 - 1126 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.12.2012
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
Although embolic protection devices (EPDs) have been shown to be beneficial in saphenous vein graft (SVG) lesions, their role in the subgroup of ostial SVG lesions has received limited study.
Methods
The coronary angiograms and procedural outcomes of 109 patients undergoing stenting of 113 ostial SVG lesions were retrospectively reviewed to determine the frequency of EPD use and the periprocedural outcomes.
Results
Ninety‐eight (87%) of the 113 lesions were suitable for EPD use, that was used in 70 lesions (71%). A Filterwire (Boston Scientific) or a SPIDER (ev3) filter were used in 54 (77%) and 16 (23%) of lesions, respectively. Difficulty retrieving the filter post stenting was encountered in eight lesions (11%) and led to stent thrombosis causing cardiac arrest in one patient (1%). Angiographic success was achieved in 111 (98%) of 113 lesions.
Conclusions
EPDs can be utilized in the majority of ostial SVG lesions, but in 11% of cases filter retrieval can be challenging and may rarely (in approximately 1%) lead to a significant complication. © 2012 Wiley Periodicals, Inc. |
---|---|
Bibliography: | istex:88598BE62458EB157EDC911EA36A526B4259BB7E ark:/67375/WNG-9LX9QL63-M Conflict of interest: Dr. Banerjee: speaker honoraria from St. Jude Medical, Medtronic, and Johnson & Johnson and research support from Boston Scientific and The Medicines Company. Dr. Brilakis: speaker honoraria from St Jude Medical and Terumo; research support from Abbott Vascular; spouse is an employee of Medtronic. ArticleID:CCD23471 Conflict of interest: Dr. Banerjee: speaker honoraria from St. Jude Medical, Medtronic, and Johnson & Johnson and research support from Boston Scientific and The Medicines Company. Dr. Brilakis: speaker honoraria from St Jude Medical and Terumo; research support from Abbott Vascular; spouse is an employee of Medtronic. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1522-1946 1522-726X |
DOI: | 10.1002/ccd.23471 |